IL240445B - A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients - Google Patents
A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patientsInfo
- Publication number
- IL240445B IL240445B IL240445A IL24044515A IL240445B IL 240445 B IL240445 B IL 240445B IL 240445 A IL240445 A IL 240445A IL 24044515 A IL24044515 A IL 24044515A IL 240445 B IL240445 B IL 240445B
- Authority
- IL
- Israel
- Prior art keywords
- ribavirin
- combination
- antiviral agents
- direct acting
- treating hcv
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 title 1
- 229960000329 ribavirin Drugs 0.000 title 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL240445A0 IL240445A0 (en) | 2015-09-24 |
| IL240445B true IL240445B (en) | 2019-07-31 |
Family
ID=50771575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL240445A IL240445B (en) | 2013-03-14 | 2015-08-09 | A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients |
| IL267927A IL267927A (en) | 2013-03-14 | 2019-07-08 | A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267927A IL267927A (en) | 2013-03-14 | 2019-07-08 | A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (enExample) |
| EP (4) | EP3318258B1 (enExample) |
| JP (3) | JP6563894B2 (enExample) |
| KR (2) | KR101853605B1 (enExample) |
| CN (3) | CN105007921B (enExample) |
| AU (3) | AU2014239322B2 (enExample) |
| BR (1) | BR112015020918A2 (enExample) |
| CA (1) | CA2901818C (enExample) |
| CY (1) | CY1121474T1 (enExample) |
| DK (1) | DK2968302T3 (enExample) |
| EA (2) | EA030482B1 (enExample) |
| ES (1) | ES2654109T3 (enExample) |
| HK (1) | HK1255257A1 (enExample) |
| HR (1) | HRP20171898T1 (enExample) |
| HU (1) | HUE036069T2 (enExample) |
| IL (2) | IL240445B (enExample) |
| LT (1) | LT2968302T (enExample) |
| MX (1) | MX2015012536A (enExample) |
| NO (1) | NO3090119T3 (enExample) |
| PL (1) | PL2968302T3 (enExample) |
| PT (1) | PT2968302T (enExample) |
| RS (1) | RS56735B1 (enExample) |
| SG (2) | SG11201507361YA (enExample) |
| SI (1) | SI2968302T1 (enExample) |
| SM (1) | SMT201800017T1 (enExample) |
| TW (2) | TW202002979A (enExample) |
| WO (1) | WO2014152635A1 (enExample) |
| ZA (1) | ZA201705080B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| EA030482B1 (ru) | 2013-03-14 | 2018-08-31 | Эббви Инк. | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv |
| MX2016005393A (es) * | 2013-10-25 | 2016-08-11 | Abbvie Inc | Metodos para tratar vhc. |
| WO2015095572A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| MX2016012722A (es) * | 2014-04-02 | 2016-12-16 | Abbvie Inc | Metodos para tratar el virus de la hepatitis c. |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| CN108778764B (zh) | 2016-01-08 | 2020-09-04 | 恩图鲁斯特咨询卡有限公司 | 具有卡片返回路径的卡片印刷机构 |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
| MX394461B (es) * | 2016-09-23 | 2025-03-24 | Abbvie Inc | Ajuste de la dosis. |
| JP2018131439A (ja) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置する方法 |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| WO2019200005A1 (en) * | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2293796A1 (en) * | 2008-06-10 | 2011-03-16 | Janssen Pharmaceutica, N.V. | Telaprevir dosing regimen |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| EA020031B1 (ru) * | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Противовирусные соединения |
| HUE028384T2 (en) * | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| CA2811203C (en) | 2011-10-21 | 2015-05-05 | Abbvie Inc. | Methods for treating hcv |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| EA030482B1 (ru) | 2013-03-14 | 2018-08-31 | Эббви Инк. | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv |
-
2014
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 PL PL14725812T patent/PL2968302T3/pl unknown
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en not_active Ceased
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 SM SM20180017T patent/SMT201800017T1/it unknown
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko not_active Expired - Fee Related
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko not_active Abandoned
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/en unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267927A (en) | A combination of directly acting antiviral agents and ribavirin for the treatment of HCV patients | |
| IL285646A (en) | Combined treatment includes mdm2 inhibitor and decitabine or cytrabine to treat AML | |
| IL264541B (en) | The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b | |
| IL240213A (en) | Sulfamoyl-arylamides and their use as anti-jaundice drugs b | |
| IL242141B (en) | The history of sulfamoylthiophenamide and their use as drugs to treat jaundice b | |
| IL241110A0 (en) | n-phenyl-carboxamide derivatives and their use as drugs for the treatment of type b jaundice | |
| SMT201700498T1 (it) | Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv | |
| SG11201509048VA (en) | Tetrapeptides derived from human c-x-c chemokines useful for treatment of various skin conditions | |
| AP2015008814A0 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |